Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1973 1
1975 4
1976 4
1977 2
1978 10
1979 8
1980 11
1981 22
1982 15
1983 21
1984 23
1985 20
1986 20
1987 16
1988 24
1989 28
1990 33
1991 37
1992 39
1993 49
1994 45
1995 63
1996 54
1997 57
1998 82
1999 61
2000 74
2001 79
2002 98
2003 156
2004 198
2005 167
2006 153
2007 138
2008 163
2009 134
2010 135
2011 163
2012 194
2013 163
2014 184
2015 150
2016 151
2017 161
2018 225
2019 256
2020 212
2021 235
2022 211
2023 188
2024 272
2025 153

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,682 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: spring2016
Page 1
Showing results for comparative law research spring2016
Search for comparative law reseach spring2016 instead (1 results)
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS, Avorn J, Sarpatwari A. Kesselheim AS, et al. JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. JAMA. 2016. PMID: 27552619 Review.
Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bea …
Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and …
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group. Hamdy FC, et al. N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14. N Engl J Med. 2016. PMID: 27626136 Free article. Clinical Trial.
BACKGROUND: The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain. ...(Funded by the National Institute for Health Research; ProtecT Current Controlled Trials number, ISRCTN20141 …
BACKGROUND: The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testi …
Country Reports.
Zawati MH, Chalmers D, Dallari SG, de Neiva Borba M, Pinkesz M, Joly Y, Chen H, Hartlev M, Leitsalu L, Soini S, Rial-Sebbag E, Hoppe N, Garani-Papadatos T, Vidalis P, Srinivas KR, Siegal G, Negri S, Hatanaka R, Al-Hussaini M, Al-Tabba' A, Motta-Murgía L, Moran LET, Hendriks A, Nnamuchi O, Isasi R, Krekora-Zajac D, Sadoun E, Ho C, Andanda P, Lee WB, Nicolás P, Mattsson T, Talanova V, Dosch A, Sprumont D, Fan CT, Hung TH, Nnamuchi O, Kaye J, Phillips A, Gowans H, Shah N, Hazel JW. Zawati MH, et al. J Law Med Ethics. 2019 Dec;47(4):582-704. doi: 10.1177/1073110519897736. J Law Med Ethics. 2019. PMID: 31957584 No abstract available.
A comparative ethical analysis of the Egyptian clinical research law.
Martin S, Ancillotti M, Slokenberga S, Matar A. Martin S, et al. BMC Med Ethics. 2024 Apr 30;25(1):48. doi: 10.1186/s12910-024-01040-0. BMC Med Ethics. 2024. PMID: 38689214 Free PMC article.
This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastruct …
This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, of …
The teaching/research trade-off in law: data from the right tail.
Ginsburg T, Miles TJ. Ginsburg T, et al. Eval Rev. 2015 Feb;39(1):46-81. doi: 10.1177/0193841X14525173. Epub 2014 Mar 20. Eval Rev. 2015. PMID: 24651660 Review.
BACKGROUND: There is a long scholarly debate on the trade-off between research and teaching in various fields, but relatively little study of the phenomenon in law. ...CONCLUSION: The recent debate on the mission of American law schools has hinged on the assu …
BACKGROUND: There is a long scholarly debate on the trade-off between research and teaching in various fields, but relatively little …
Theory and methods in comparative drug and alcohol policy research: Response to a review of the literature.
Burris S. Burris S. Int J Drug Policy. 2017 Mar;41:126-131. doi: 10.1016/j.drugpo.2016.11.011. Epub 2016 Dec 29. Int J Drug Policy. 2017. PMID: 28041769 Free PMC article. Review.
Comparative drug and alcohol policy analysis (CPA) is alive and well, and the emergence of robust alternatives to strict prohibition provides exciting research opportunities. ...This problem is aided and abetted by the all-too-common omission of theory from the conc …
Comparative drug and alcohol policy analysis (CPA) is alive and well, and the emergence of robust alternatives to strict prohibition …
Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
Hao Y, Thomas A. Hao Y, et al. Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):447-54. doi: 10.1586/14737167.2013.815401. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23977973 Review.
Special attention is paid on two issues: the position of HTA in coverage decision making and the role of economic assessment in evaluation processes. Although law makers in the USA have barred the use of NICE's cost/quality-adjusted life year or similar health economics ap …
Special attention is paid on two issues: the position of HTA in coverage decision making and the role of economic assessment in evaluation p …
Protecting children with disabilities in armed conflict.
Wild H, Bazzi O, Lord J. Wild H, et al. Lancet Child Adolesc Health. 2024 Sep;8(9):616-618. doi: 10.1016/S2352-4642(24)00129-9. Epub 2024 Jun 18. Lancet Child Adolesc Health. 2024. PMID: 38906165 No abstract available.
4,682 results